Immunoregulatory Antibodies and Uses Thereof
A combination antibody therapy for treating B cell malignancies using an immunoregulatory antibody, especially an anti-B7, anti-CD23, or anti-CD40L antibody and a B cell depleting antibody, especially anti-CD19, anti-CD20, anti-CD22 or anti-CD37 antibody is provided. Preferably, the combination therapy will comprise anti-B7 and anti-CD20 antibody administration.
1 . A method of treating a mammal suffering from or predisposed to a neoplastic disorder comprising the steps of:
administering a therapeutically effective amount of a first immunoregulatory antibody to said mammal; and
administering a therapeutically effective amount of a second immunoregulatory antibody or a B cell depleting antibody to said mammal wherein said first and second immunoregulatory antibodies bind to different antigens and the first immunoregulatory antibody and the second immunoregulatory antibody or B cell depleting antibody may be administered in any order or concurrently.
2 . The method of claim 1 wherein said first immunoregulatory antibody reacts with or binds to B7 antigen.
3 . The method of claim 2 comprising the administration of a second immunoregulatory antibody wherein said second immunoregulatory antibody reacts with or binds to an antigen selected from the group consisting of CD40L, CD40, and CD23.
4 . The method of claim 3 wherein said second immunoregulatory antibody binds to CD40L antigen.
5 . The method of claim 1 wherein said first immunoregulatory antibody, said second immunoregulatory antibody and said B cell depleting antibody are monoclonal antibodies.
6 . The method of claim 5 wherein said monoclonal antibodies are selected from the group consisting of chimeric antibodies and humanized antibodies.
7 . The method of claim 6 wherein at least one of said monoclonal antibodies is a chimeric antibody and said chimeric antibody is primatized.
8 . The method of claim 7 wherein said primatized antibody is IDEC-114.
9 . The method of claim 1 wherein said neoplastic disorder is selected from the group consisting of relapsed Hodgkin's disease, resistant Hodgkin's disease high grade, low grade and intermediate grade non-Hodgkin's lymphomas, B cell chronic lymphocytic leukemia (B-CLL), lymhoplasmacytoid lymphoma (LPL), mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large cell lymphoma (DLCL), Burkitt's lymphoma (BL,), AIDS-related lymphomas, monocytic B cell lymphoma, angioimmunoblastic lymphoadenopathy, small lymphocytic; follicular, diffuse large cell; diffuse small cleaved cell; large cell immunoblastic lymphoblastoma; small, non-cleaved; Burkitt's and non-Burkitt's; follicular, predominantly large cell; follicular, predominantly small cleaved cell; and follicular, mixed small cleaved and large cell lymphomas.
10 . The method of claim 1 comprising the administration of a first immunoregulatory antibody and a B cell depleting antibody.
11 . The method of claim 10 wherein said B cell depleting antibody reacts with or binds to an antigen selected from the group consisting of CD20, CD19, CD22 and CD37 antigens.
12 . The method of claim 11 wherein said B cell depleting antibody reacts with or binds to CD20.
13 . The method of claim 12 wherein said B cell depleting antibody is associated with a radioisotope.
14 . The method of claim 12 wherein said B cell depleting antibody is rituximab.
15 . The method of claim 14 wherein said first immunoregulatory antibody is IDEC-114.
16 . The method of claim 14 wherein said first immunoregulatory antibody is IDEC-131.
17 . The method of claim 1 further comprising the step of administering a chemotherapeutic agent.
18 . A method of treating a mammal suffering from or predisposed to a neoplastic disorder comprising the steps of:
administering a therapeutically effective amount of at least one chemotherapeutic agent to said mammal; and
administering a therapeutically effective amount of at least one immunoregulatory antibody to said mammal wherein said chemotherapeutic agent and said immunoregulatory antibody may be administered in any order or concurrently.
19 . The method of claim 18 wherein said immunoregulatory antibody binds to an antigen selected from the group consisting of B7, CD40, CD40L and CD23 antigens.
20 . The method of claim 19 wherein said immunoregulatory antibody comprises a monoclonal antibody.
21 . The method of claim 20 wherein said monoclonal antibody is selected from the group consisting of chimeric antibodies and humanized antibodies.
22 . The method of claim 21 wherein said immunoregulatory antibody is a chimeric antibody and said chimeric antibody is primatized.
23 . The method of claim 22 wherein said primatized antibody is IDEC-114.
24 . The method of claim 21 wherein said monoclonal antibody is humanized.
25 . The method of claim 24 wherein said humanized antibody comprises IDEC-131.
26 . The method of claim 18 wherein said neoplastic disorder is selected from the group consisting of relapsed Hodgkin's disease, resistant Hodgkin's disease high grade, low grade and intermediate grade non-Hodgkin's lymphomas, B cell chronic lymphocytic leukemia (B-CLL), lymhoplasmacytoid lymphoma (LPL), mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large cell lymphoma (DLCL), Burkitt's lymphoma (BL), AIDS-related lymphomas, monocytic B cell lymphoma, angioimmunoblastic lymphoadenopathy, small lymphocytic; follicular, diffuse large cell; diffuse small cleaved cell; large cell immunoblastic lymphoblastoma; small, non-cleaved; Burkitt's and non-Burkitt's: follicular, predominantly large cell; follicular, predominantly small cleaved cell; and follicular, mixed small cleaved and large cell lymphomas.
27 . The method of claim 18 further comprising the step of administering a B cell depleting antibody.
28 . The method of claim 27 wherein said B cell depleting antibody reacts with or binds to CD20 antigen.
29 . A method of treating a mammal suffering from or predisposed to a neoplastic disorder comprising the steps of:
administering a therapeutically effective amount of a first immunoregulatory antibody to said mammal; and
administering a therapeutically effective amount of a second immunoregulatory antibody to said mammal wherein said first and second immunoregulatory antibodies bind to different antigens and the first immunoregulatory antibody and the second immunoregulatory antibody may be administered in any order or concurrently.
30 . The method of claim 29 wherein said first and second immunoregulatory antibodies bind to an antigen selected from the group consisting of B7, CD40, CD40L and CD23 antigens.
31 . The method of claim 30 wherein said first immunoregulatory antibody reacts with or binds to B7 antigen and said second immunoregulatory antibody reacts with or binds to CD40L antigen.
32 . The method of claim 31 wherein said first immunoregulatory antibody comprises IDEC-114 and said second immunoregulatory antibody comprises IDEC-131.
33 . The method of claim 32 wherein said neoplastic disorder is selected from the group consisting of relapsed Hodgkin's disease, resistant Hodgkin's disease high grade, low grade and intermediate grade non-Hodgkin's lymphomas, B cell chronic lymphocytic leukemia (B-CLL), lymhoplasmacytoid lymphoma (LPL), mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large cell lymphoma (DLCL), Burkitt's lymphoma (BL), AIDS-related lymphomas, monocytic B cell lymphoma, angioimmunoblastic lymphoadenopathy, small lymphocytic; follicular, diffuse large cell; diffuse small cleaved cell; large cell immunoblastic lymphoblastoma; small, non-cleaved; Burkitt's and non-Burkitt's; follicular, predominantly large cell; follicular, predominantly small cleaved cell; and follicular, mixed small cleaved and large cell lymphomas.
34 . The method of claim 32 further comprising the step of administering a therapeutically effective amount of at least one chemotherapeutic agent.
35 . The method of claim 32 further comprising the step of administering at least one B cell depleting antibody.
36 . The method of claim 35 wherein said B cell depleting antibody reacts with or binds to an antigen selected from the group consisting of CD20, CD19, CD22 and CD37 antigens.
37 . The method of claim 36 wherein said B cell depleting antibody reacts with or binds to CD20.
38 . The method of claim 37 wherein said B cell depleting antibody in rituximab.
39 - 50 . (canceled)